← Scroll for more →
Financial Statements — DRUG
Balance Sheet
(in millions CAD)| Metric | Q4 2024 | Q4 2023 | Q4 2022 | Q4 2021 |
|---|---|---|---|---|
| Cash & Equivalents | 5.72 | 6.75 | 11.63 | 19.76 |
| Total Current Assets | 5.99 | 6.81 | 11.95 | 20.04 |
| Total Non-current Assets* | 0.12 | 0.07 | 0.14 | 0.00 |
| Total Assets | 6.10 | 6.88 | 12.09 | 20.04 |
| Total Current Liabilities | 0.53 | 0.28 | 1.47 | -- |
| Total Non-current Liabilities* | 0.04 | 0.00 | 0.07 | -- |
| Total Liabilities | 0.57 | 0.28 | 1.54 | 0.64 |
| Retained Earnings | (34.35) | (31.55) | (24.17) | (9.21) |
| Total Stockholder Equity | 5.54 | 6.60 | 10.54 | 19.40 |
← Scroll for more columns →
* Derived from reported values
Income Statement
(in millions CAD)| Metric | Q4 2021 |
|---|---|
| Net Income | (8.65) |
← Scroll for more columns →